World Hepatitis Day 2020: Preventing mother-to-child hepatitis transmission
Click Here to Manage Email Alerts
“Hepatitis-free future.” is this year’s World Hepatitis Day theme. The focus is the prevention of hepatitis B transmission between mothers and newborns.
The following reports include data on mother-to-child hepatitis transmission, screening pregnant women for hepatitis C virus and DAA treatment for children with HCV.
In Tennessee, just 23% of at-risk infants are tested for HCV
In Tennessee, only 23% of infants who were exposed to hepatitis C virus were tested for it, including just one in 10 Black infants, study results showed. Read more.
Estimated global prevalence of pediatric HCV at more than 3 million
An analysis of peer-reviewed articles provided global prevalence estimates of hepatitis C virus in children, according to data from a modelling study. Read more.
Should all pregnant women in the US be screened for hepatitis C?
Infectious Diseases in Children asked Jordan J. Feld, MD, MPH, the R. Phelan Chair in Translational Liver Disease Research at the University of Toronto, and Anna Suk-Fong Lok, MD, professor of gastroenterology, hepatology and internal medicine at the University of Michigan, about the importance of universal HCV testing in pregnant women and why physicians may argue against it. Read more.
FDA approves Epclusa for pediatric HCV
Epclusa is now available for the treatment of children with any of the six genotypes of hepatitis C virus after obtaining approval from the FDA, according to a press release. Read more.
DAAs change treatment landscape for children with HCV
From 2013 through 2016, an estimated 2.4 million adults in the United States had a current hepatitis C virus infection. A study published in The American Journal of Public Health reported that the infection rate increased more than twofold between 2004 and 2014 as a result of the opioid epidemic. Read more.
FDA expands Mavyret approval for adults, children with any HCV genotype
The FDA has expanded the approval of Mavyret for a treatment duration of 8 weeks to include treatment-naive adults and children aged 12 years and older with chronic hepatitis C genotype 1 through 6 and compensated cirrhosis. Read more.